An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In addition to the traditional method of vaccine development, the mRNA coronavirus vaccine, which is attractive as a challenging vaccination, recently opened a new era in vaccinology. Here we describe the EG-COVID which is a novel liposome-based mRNA candidate vaccine that encodes the spike (S) protein of SARS-CoV-2 with 2P-3Q substitution in European variant. We developed the mRNA vaccine platform that can be lyophilized using liposome-based technology. Intramuscular injection of the EG-COVID elicited robust humoral and cellular immune response to SARS-CoV-2. Furthermore, sera obtained from mice successfully inhibited SARS-CoV-2 viral infection into Vero cells. We developed EG-COVID and found it to be effective based on in vitro data, and we plan to initiate a clinical trial soon. Since EG-COVID is a lyophilized mRNA vaccine that is convenient for transportation and storage, accessibility to vaccines will be significantly improved.
Article activity feed
-
SciScore for 10.1101/2021.03.22.436375: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Immunization of mice: For immunogenicity studies, 6-week-old female B6C3F1 mice (SLC, Japan) were randomly assigned into experimental groups (n = 6). Blinding not detected. Power Analysis not detected. Sex as a biological variable Bioluminescence imaging: For bioluminescence imaging studies, 6-week-old female Balb/c nude or C57BL/6N mice (SLC, Japan) were used. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The primary and secondary antibodies were SARS-CoV-2-S1 (Novus, Centennial, CO, USA), beta-actin (Cell signaling, Danvers, MA, USA) and anti-rabbit (Invitrogen, Thermo Scientific, Waltham, MA, USA). beta-ac…SciScore for 10.1101/2021.03.22.436375: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization Immunization of mice: For immunogenicity studies, 6-week-old female B6C3F1 mice (SLC, Japan) were randomly assigned into experimental groups (n = 6). Blinding not detected. Power Analysis not detected. Sex as a biological variable Bioluminescence imaging: For bioluminescence imaging studies, 6-week-old female Balb/c nude or C57BL/6N mice (SLC, Japan) were used. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The primary and secondary antibodies were SARS-CoV-2-S1 (Novus, Centennial, CO, USA), beta-actin (Cell signaling, Danvers, MA, USA) and anti-rabbit (Invitrogen, Thermo Scientific, Waltham, MA, USA). beta-actinsuggested: Noneanti-rabbitsuggested: NoneAntigen-specific antibody titer was determined by end-point dilution ELISA. Antigen-specificsuggested: NoneBound antibodies were detected with HRP-conjugated goat anti-mouse total IgG antibody (Jackson, PA, USA) diluted 1:5000 for 1 hour at 37°C. anti-mouse total IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Cell culture and mRNA transfection: HEK-293T cell was obtained from ATCC (Manasass, VA, USA). HEK-293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)EG-COVID 001, 002, 003 and 004 (10 ug mRNA containg complex each) were introduced into 293T cells by 18 hour incubation in OPTi-MEM (Thermo Scientific, MA, USA). 293Tsuggested: NoneVero cells were seeded at 8 × 105 cells/well in 6 well plates and cultured overnight. Verosuggested: NoneExperimental Models: Organisms/Strains Sentences Resources Bioluminescence imaging: For bioluminescence imaging studies, 6-week-old female Balb/c nude or C57BL/6N mice (SLC, Japan) were used. Balb/c nudesuggested: NoneC57BL/6Nsuggested: RRID:MGI:5825016)Immunization of mice: For immunogenicity studies, 6-week-old female B6C3F1 mice (SLC, Japan) were randomly assigned into experimental groups (n = 6). B6C3F1suggested: RRID:IMSR_JAX:100010)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 28. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-